Carboplatin

Retinoblastoma, advanced Thymoma, Advance Directives + 20 more

Treatment

3 FDA approvals

20 Active Studies for Carboplatin

What is Carboplatin

Carboplatin

The Generic name of this drug

Treatment Summary

Carboplatin is a chemotherapy drug used to treat advanced ovarian cancer. It was first tested in 1982 and was approved by the FDA in 1989. Carboplatin is an analog of cisplatin, but it has fewer side effects such as kidney damage and vomiting.

Carboplatin

is the brand name

image of different drug pills on a surface

Carboplatin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Carboplatin

Carboplatin

2004

69

Approved as Treatment by the FDA

Carboplatin, also called Carboplatin, is approved by the FDA for 3 uses including Advanced Ovarian Carcinoma and initial treatment .

Advanced Ovarian Carcinoma

Used to treat Advanced Ovarian Carcinoma in combination with Carboplatin

initial treatment

Used to treat initial treatment in combination with Carboplatin

Ovarian Neoplasms

Used to treat Advanced Ovarian Carcinoma in combination with Carboplatin

Effectiveness

How Carboplatin Affects Patients

Carboplatin is a drug used to fight certain types of cancer, particularly ovarian cancer. It takes a few weeks for the drug to become effective, and care must be taken to ensure patients are taking the correct dosage. Patients should be aware that the drug could cause bone marrow suppression and anemia.

How Carboplatin works in the body

Carboplatin works by directly damaging DNA. It attaches alkyl groups to the nucleotides in the genetic material, causing it to break when repair enzymes attempt to fix it. Additionally, it can form links between two different strands of DNA, preventing them from separating for transcription or replication. Lastly, carboplatin can cause mutations in the DNA.

When to interrupt dosage

The suggested dosage of Carboplatin is based on the diagnosed affliction, including Pharmacotherapy, Carcinoma, Neuroendocrine and advanced Testicular cancer. The measure is contingent upon the technique of issuance, as specified in the table beneath.

Condition

Dosage

Administration

melanoma

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Esophageal Neoplasms

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Pharmacotherapy

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Uterine Cervical Neoplasms

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Carcinoma, Non-Small-Cell Lung

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Palliative Treatment

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Endometrial Neoplasms

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Testicular Neoplasms

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Head and Neck Neoplasms

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Hodgkin Disease

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Metastatic Breast Cancer

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Ovarian Neoplasms

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Recurrence

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

initial treatment

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Retinoblastoma

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Advance Directives

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

conditioning regimens for allogeneic stem cell transplantation therapy

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Advance Directives

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Lymphoma, Non-Hodgkin

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Advance Directives

, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL

, Injection, Intravenous, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Carboplatin Contraindications

Condition

Risk Level

Notes

Hemorrhage

Do Not Combine

Bone Marrow

Do Not Combine

There are 20 known major drug interactions with Carboplatin.

Common Carboplatin Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Carboplatin is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Carboplatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Carboplatin is combined with Abatacept.

Abetimus

Major

The risk or severity of adverse effects can be increased when Carboplatin is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Carboplatin is combined with Acteoside.

Carboplatin Toxicity & Overdose Risk

Someone who has overdosed on carboplatin may suffer from low white blood cell levels and liver damage. Treatment should involve relieving symptoms and providing supportive care, such as delaying the next dose.

image of a doctor in a lab doing drug, clinical research

Carboplatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Carboplatin?

148 active clinical trials are currently assessing the potential of Carboplatin to treat Metastatic Breast Cancer, Advance Directives and conditioning regimens for Allogeneic Stem Cell Transplantation Therapy.

Condition

Clinical Trials

Trial Phases

conditioning regimens for allogeneic stem cell transplantation therapy

0 Actively Recruiting

Advance Directives

0 Actively Recruiting

Esophageal Neoplasms

0 Actively Recruiting

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

melanoma

0 Actively Recruiting

Recurrence

0 Actively Recruiting

Advance Directives

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Carcinoma, Non-Small-Cell Lung

23 Actively Recruiting

Phase 2, Phase 1, Not Applicable, Phase 3

initial treatment

0 Actively Recruiting

Lymphoma, Non-Hodgkin

0 Actively Recruiting

Ovarian Neoplasms

0 Actively Recruiting

Malignant Mesothelioma

15 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable

Testicular Neoplasms

0 Actively Recruiting

Pharmacotherapy

0 Actively Recruiting

Retinoblastoma

5 Actively Recruiting

Phase 2, Phase 1

Endometrial Neoplasms

0 Actively Recruiting

Head and Neck Neoplasms

0 Actively Recruiting

advanced Thymoma

0 Actively Recruiting

Hodgkin Disease

2 Actively Recruiting

Phase 2, Phase 1

Carboplatin Reviews: What are patients saying about Carboplatin?

5

Patient Review

9/19/2009

Carboplatin for Non-Small Cell Lung Cancer

This drug was better than anticipated. I had no issues with nausea or tiredness, though resting was key. It took a bit longer to get my white blood cell count back up, but a shot of Neulasta helped out a lot.

5

Patient Review

4/14/2010

Carboplatin for Cancer of the Ovary

I had eight doses of Taxol starting in 2007, and after a rising CA125, I've now had four more doses. I had a mild allergic reaction to the fourth dose, so I'll be premedicating for the fifth.

5

Patient Review

1/9/2009

Carboplatin for Cancer of the Ovary

5

Patient Review

4/14/2009

Carboplatin for Cancer of the Ovary

5

Patient Review

4/9/2014

Carboplatin for Cancer of the Ovary

I was cancer-free within weeks of starting this treatment, and I couldn't have been more pleased with how easy it was to take.

4.7

Patient Review

6/18/2010

Carboplatin for Non-Small Cell Lung Cancer

I was diagnosed with ovarian cancer in 2006 and had three treatments of Taxol and Carboplatin. After CA-125 increased in 2009, I had six treatments. I had an allergic reaction from the carbo during treatment #2. Subsequent treatments included steriods prior to the infusion. I had no nausea at all - fatigue for a few days after then nominally tired. I had Neulasta shots right after my treatments to help with my white blood count.

4.7

Patient Review

7/21/2010

Carboplatin for Breast Cancer that has Spread to Another Part of the Body

My mom was diagnosed with stage IV lung cancer in Dec. 09. Carboplatin was one of the chemo drugs used to treat her cancer. After only one treatment, the doctors said that the Carboplatin damaged my mom's kidneys and she passed away on April 22nd.

4.7

Patient Review

5/19/2012

Carboplatin for Non-Small Cell Lung Cancer

My husband died as a result of being overmedicated.

4.3

Patient Review

11/24/2010

Carboplatin for Breast Cancer that has Spread to Another Part of the Body

This drug, in conjunction with Taxol IV, was part of my chemotherapy treatment post-lung surgery in 2005. I'm pleased to report that I've been cancer-free for over five years now. The treatments made me tired, but I didn't experience any other negative side effects.

4.3

Patient Review

3/11/2011

Carboplatin for Non-Small Cell Lung Cancer

It helps me part of the time. I do it with gemzar

4

Patient Review

11/18/2009

Carboplatin for Cancer of the Ovary

This drug, in combination with taxol, was incredibly effective. I did have an allergic reaction to the taxol, but by doubling up on steroids, I was able to manage it. The outcome was well worth the side effects!

3.7

Patient Review

5/10/2013

Carboplatin for Cancer Involving the Head or Neck

This drug was unfortunately ineffective against my clear cell cancer. I wasted six months because this was the "standard" treatment for endometrial cancer rather than seeking a more targeted approach.

2.3

Patient Review

2/14/2011

Carboplatin for Cancer of the Cervix

I've only had two treatments thus far. No serious side effects that I can tell, but it's hard to say if it's truly effective yet or not.

2

Patient Review

1/17/2022

Carboplatin for Locally Advanced Breast Carcinoma

One of the less common side effects of this medication is a drastic reduction in blood count. In my case, this happened after the first dose. My doctor lowered the dosage and tried again, but I still needed multiple transfusions. Even after discontinuing use, I'm still anemic and have very low white blood cell and platelet counts 12 months later.

2

Patient Review

4/30/2010

Carboplatin for Non-Small Cell Lung Cancer

This was my first time trying this treatment and it didn't work very well for me.

1.7

Patient Review

12/27/2012

Carboplatin for Cancer in the Lining of the Uterus

My father was diagnosed with mesotheloma in February 2012 and started chemotherapy soon after. Unfortunately, he had trouble breathing shortly after his first treatment and ended up in the hospital. He is currently on dialysis as a result of kidney failure.

1.7

Patient Review

6/6/2012

Carboplatin for Small Cell Cancer of the Lung

I lost a significant amount of hair, but didn't experience any nausea. I've been cancer free for 20 months now.

1

Patient Review

9/6/2011

Carboplatin for Non-Small Cell Lung Cancer

My husband has undergone this treatment twice, and so far it's working well the second time around. He didn't lose any hair, which was a big problem last time. Additionally, he hasn't experienced any nausea.

1

Patient Review

2/14/2010

Carboplatin for Breast Cancer that has Spread to Another Part of the Body

I experienced some fatigue and nausea with this treatment, but thankfully another drug was able to help with that. I'm now cancer-free four and a half years later.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about carboplatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of chemo is carboplatin?

"Carboplatin is similar to cisplatin but has a platinum atom complexed with glucose.

Carboplatin is a drug that is used to treat cancer. It is classified as an alkylating agent, which are drugs that are used to kill cancer cells. Carboplatin is similar to cisplatin, but it has a platinum atom complexed with glucose."

Answered by AI

Is carboplatin a strong chemo?

"If you experience numbness or tingling, tell your doctor so they can monitor the symptoms. Carboplatin may cause severe tingling in some cases and stopping treatment may be necessary."

Answered by AI

What are the common side effects of carboplatin?

"The symptoms of the illness include nausea, vomiting, diarrhea, constipation, sores in the mouth and throat, pain, burning, or tingling in the hands or feet."

Answered by AI

Is carboplatin an immunotherapy or chemo?

"The standard treatment for this type of cancer generally includes the use of the chemotherapy drugs Paclitaxel and carboplatin."

Answered by AI

Clinical Trials for Carboplatin

Image of AHN West Penn Hospital in Pittsburgh, United States.

Fast TILs + Interleukin-2 for Mesothelioma

18 - 79
All Sexes
Pittsburgh, PA

This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltrating T-cells (PIT). It is administered through a pleural catheter along with the drug Interleukin-2 (IL-2). Based on previous research it is believed that it may help fight the tumor and relieve symptoms. As a participant, their pleural fluid will be collected and the PIT cells will be isolated and expanded in the lab to create the ACT product. Before receiving the ACT product through their pleural catheter, they will undergo outpatient lymphodepleting chemotherapy. LDC is a standard procedure for many approved immunotherapy treatments Following the infusion, they'll receive IL-2 through the catheter for two days to stimulate the expanded PIT cells. The active treatment phase lasts about three weeks, with follow-up visits over five years at AHN West Penn Hospital, potentially requiring a hospital stay of up to six days. Blood samples will be taken to monitor their response. As this is a first-in-human study, treatment carries an unknown risk up to and including death from toxicity. However, the risks of similar immunotherapy treatments are well documented.

Phase 1
Recruiting

AHN West Penn Hospital

David Bartlett, MD

Miltenyi Biotec, Inc.

Image of NEXT Oncology in San Antonio, United States.

PF-08046876 for Bladder Cancer

18+
All Sexes
San Antonio, TX

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Phase 1
Recruiting

NEXT Oncology (+11 Sites)

Pfizer CT.gov Call Center

Pfizer

Have you considered Carboplatin clinical trials?

We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Go to Trials
Image of OHSU Knight Cancer Institute-Northwest Portland in Portland, United States.

Precision Medicine Approach for Cancer

18+
All Sexes
Portland, OR

This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy \[SMMART\])-adaptive clinical treatment \[ACT\]) works in treating patients with sarcoma, prostate, breast, ovarian or pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). SMMART testing uses genetic and protein tests to learn how cancer changes and to understand what drugs may work against a person's cancer or why drugs stop working. These test results are reviewed by a group of physicians and scientists during a SMMART tumor board who then recommend precision therapy.

Phase 2
Waitlist Available

OHSU Knight Cancer Institute-Northwest Portland (+1 Sites)

Charles D Lopez, MD, PhD

AstraZeneca

Image of MedStar Georgetown University Hospital in Washington, United States.

Palliative Care Interventions for Serious Illness

18+
All Sexes
Washington, United States

This stepped-wedge, cluster randomized pragmatic trial among 9 MedStar hospitals for patients with serious illness and unmet palliative care (PC) needs will test two interventions embedded within the electronic health record (EHR): (1) a PC needs triggered alert to opt-in to PC consults nudging hospital clinicians to order specialty PC consults for eligible inpatients, and (2) a palliative care needs triggered alert with an opt-out to palliative care consults. The trial will compare the interventions effects to usual care, focusing on completed PC consults during the hospital encounter and other secondary outcomes. The trial also includes an embedded mixed methods study to explore factors influencing the effectiveness and equity of intervention implementation.

Phase 3
Waitlist Available

MedStar Georgetown University Hospital (+10 Sites)

Michael Harhay, PhD, MPH

Have you considered Carboplatin clinical trials?

We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Go to Trials
Image of University of Iowa Hospitals and Clinics in Iowa City, United States.

Imaging for Lung Cancer

18+
All Sexes
Iowa City, IA

This pilot study uses \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. The study's main objectives are to quantify the change in \[18F\]F AraG PET signal before and while on CkIT therapy and to correlate this change in \[18F\]F AraG PET signal with radiographic response. To explore these objectives, eligible subjects will undergo pre- and on - CkIT treatment \[18F\]F AraG PET/CT scans, and will be followed up for 12 months for assessment of radiographic and clinical outcomes. This study is a single-site, open label, non randomized, single arm pilot trial. Patients and care providers will not be blinded to any part of the study.

Phase 2
Recruiting

University of Iowa Hospitals and Clinics

Muhammad Furqan, M.D.

CellSight Technologies, Inc.

Image of Mayo Clinic in Florida in Jacksonville, United States.

At-Home vs Clinic-Based Therapy for Advanced Cancer

18+
All Sexes
Jacksonville, FL

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and financial burden for patients and their families. The logistics and costs of navigating cancer treatments have become a principal contributor to patients' reduced quality of life. It is therefore important to reduce the burden of cancer in the lives of patients and their caregivers, and a vital aspect of this involves moving beyond traditional hospital and clinic-based care and evaluate innovative care delivery models with virtual capabilities. Providing cancer treatment at-home, versus in the clinic, may help reduce psychological and financial distress and increase treatment compliance, especially for marginalized patients and communities.

Phase 2
Recruiting

Mayo Clinic in Florida (+1 Sites)

Roxana S. Dronca, MD

Have you considered Carboplatin clinical trials?

We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Go to Trials